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In November 2010, NDM-1-producing Klebsiella pneumoniae (NDMKP) was identified for the first time in South Korea from
four patients with no history of traveling abroad who stayed for 21 to 205 days in a tertiary care hospital. All were sequence type
(ST) 340 and had nearly identical XbaI pulsed-field gel electrophoresis (PFGE) patterns. The blaNDM-1-carrying plasmids were in
the IncN group, with sizes ranging from 50 to 200 kb. These findings suggest that NDMKP had already been introduced into
South Korea before this clustering was found.
NDM-1 is a metallo--lactamase (MBL) first identified in car-bapenem-resistantKlebsiella pneumoniae and Escherichia coli
isolates from Swedish patients transferred fromNewDelhi, India,
in 2008 (26). In a short period, NDM-1-producing Enterobacteri-
aceae have been reported in Africa, Asia, Australia, Canada, Eu-
rope, and the United States, starting in the United Kingdom, and
many of those had links with India or Pakistan (15). Carbapenem-
resistant Enterobacteriaceae (CRE) with acquired carbapenemases
are rare in South Korean hospitals (8, 11).
In this study, we described four patients colonized by NDM-1-
producing K. pneumoniae (NDMKP) who were hospitalized at a
2,700-bed tertiary care hospital in Seoul, South Korea. We char-
acterized the genotype and phenotype of the strains. All isolates
were identified as carbapenem-resistantK. pneumoniae by theMi-
croScan Neg Breakpoint Combo Panel type 44 (Siemens, West
Sacramento, CA). The modified Hodge tests using ertapenem
disks (4) were weakly positive, and a KPC-MBL Confirm ID kit
(RoscoDiagnostica, Taastrup, Denmark) showed that onlymero-
penem-dipicolinic acid tablets revealed an increase of the inhibi-
tion zone compared to that of meropenem tablets. Two NDMKP
isolates were obtained from urine cultures, and the others were
isolated from stool surveillance cultures (Table 1). Four patients
were hospitalized for 21 to 205 days and received meropenem for
8 to 47 days before isolation of NDMKP. Three of them were
admitted to the medical intensive care unit (MICU), but their
periods in the MICU did not overlap. The remaining patient
stayed at a surgical ward after a liver transplantation. There was no
history of travel abroad found. None of the four patients was
treated to eradicate NDMKP because all were considered to be
colonizers. Stool surveillance cultures were performed on 71 pa-
tients who shared rooms or intensive care units with the
patients carrying NDMKP, but only a carbapenemase-negative,
carbapenem-resistant K. pneumoniae strain was isolated. The
NDM-1-producing strains might have been introduced earlier in
the hospital before this clustering was detected. Interestingly,
three patients spontaneously decolonized, but one patient (case 4)
carriedNDMKP formore than 7months. Prolonged colonization
of NDM-1-producing Escherichia coli has been reported in a pa-
tient hospitalized for 13 months without exposure to carbapen-
ems or overt infection by such bacteria (20). Prolonged carriage in
the gut can be a factor facilitating the spread ofNDM-1-producing
Enterobacteriaceae.
MICs of relevant antimicrobials were confirmed by the agar
dilution method (Table 2). The interpretative breakpoints for
tigecycline and colistin by the European Committee on Antimi-
crobial Susceptibility Testing and the breakpoints for other anti-
microbials by the Clinical and Laboratory Standards Institute
were used (4, 6). Three strains (F181, E1454, and F528) were
highly resistant to imipenem and meropenem, but one from pa-
tient 4 (E5026) was susceptible to imipenem, with a MIC of 1
g/ml, and intermediate tomeropenem. Colistin, tigecycline, and
gentamicin remained active for all strains, and tobramycin, ami-
kacin, and aztreonam were variably active. The blaNDM-1 gene is
usually associated with high-level MICs of carbapenems (10).
Emergence of strains with low-level MICs suggested that addi-
tional mechanisms, such as an efflux pump or porin loss, may be
involved in carbapenem resistance in NDM-1 producers. Detec-
tion of NDM-1 CRE is impeded when strains have lower-level
imipenem and meropenemMICs (3).
Extended-spectrum -lactamase (ESBL) and plasmid-medi-
atedAmpC-lactamase (PABL) productionwas initially screened
by the combined disk tests using cefotaxime-clavulanic acid, ce-
fotaxime disks (4), and disks with boronic acid added (23). ESBL
phenotypes were positive only in strain E5026 and its transconju-
gant, and PABL activity was detected in all isolates (Table 2). The
presence of known MBLs (blaVIM, blaIMP, blaSPM-1, blaGIM-1,
blaAIM-1, blaSIM-1, and blaNDM-1) (13, 24), ESBLs (blaTEM, blaSHV,
and blaCTX-M) (25), and PABL genes (17) were determined using
PCR. We also aimed to detect ISAba125 and 16S rRNAmethylase
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(armA) by using the published primers (7). All PCRproducts were
directly sequenced. PCR assays detectingMBL genes were positive
only for blaNDM-1. E5026 and its transconjugant carried a blaCTX-
M-15-type gene (Table 2). All of them carried blaDHA-1 genes.
armA-specific PCRs were all negative. ISAba125, which is a com-
mon feature of blaNDM-1-positive Enterobacteriaceae, was located
upstream of each blaNDM-1 gene (19). The absence of armA is
related to susceptibility to gentamicin, a trait which is not found in
NDM-1 producers of Indian origin (26).
Platematingwas performedusingE. coli J53 (azide resistant) as
TABLE 1 Clinical features of the four patients with blaNDM-1-carrying Klebsiella pneumoniae
a
Patient
Age (yr)/gender and
underlying disease
Admission date, date
discharged or expired, and
clinical outcome Ward (dates of hospital stayb)
Period of isolation of NDMKP,
specimen type, and pathogenicity
Carbapenem(s) administered
before isolation of NDMKP
(no. of days before isolation)
1 71/F; pyogenic spondylitis 3 June 2010; 21 January 2011;
improved
GW124 (3 June–5 July), MICU1 (5
July–16 July), GW134 (16 July–
30 July), MICU1 (30 July–3
August), GW134 (3 August–21
January 2011)
5 November 2010–31 December 2010;
stool; colonizer
Meropenem (8)
2 52/M; dermatomyositis
interstitial lung disease
7 October 2010; 16 December
2010; expired from
pneumothorax
MICU1 (7 October–12 October),
MICU2 (12 October–16
December)
8 November 2010–12 November
2010; urine; colonizer
Meropenem (16)
3 71/M; vertebral
osteomyelitis
31 August 2010; 15 December
2010; improved
GW134 (31 August–2 September),
MICU2 (2 September–17
September), GW134 (17
September–15 December)
16 November 2010/stool/colonizer Meropenem (22), ertapenem
(13)
4 59/M; liver transplantation
due to HBV-associated
liver cirrhosis
28 July 2010; July 2011;
improved
GW91 (28 July–3 August), MICU1
(3 August–12 August), SICU
(12 August–3 September),
GW102 (3 September–19
September), SICU (19
September–26 September),
GW102/SICU (26 September to
last follow-up on 30 June 2011)
30 November 2010–6 December 2010/
urine/colonizer; 15 December
2010–22 January
2011/stool/colonizer
Meropenem (47)
a NDMKP, NDM-1-producing Klebsiella pneumoniae; GW, general ward; MICU, medical intensive care unit; SICU, surgical intensive care unit; M, male; F, female.
b In 2010 unless specified.
TABLE 2 Antimicrobial susceptibility profiles of the four NDM-1-producing isolatesa
Antimicrobial, gene, or other
characteristic
MIC (g/ml) and susceptibility, gene presence, and plasmid size(s) of each strainb
F181 from
patient 1
(wild type)
E1454 from patient 2 F528 from patient 3 E5026 from patient 4
Wild type Transconjugant Wild type Transconjugant Wild type Transconjugant
Antimicrobials
Ampicillin 128, R 128, R 128, R 128, R 128, R 128, R 128, R
Piperacillin 128, R 128, R 32, I 128, R 64, I 128, R 128, R
Cephalothin 128, R 128, R 128, R 128, R 128, R 128, R 128, R
Cefotaxime 128, R 128, R 128,R 128, R 128, R 128, R 128, R
Ceftazidime 128, R 128, R 128, R 128, R 128, R 128, R 128, R
Cefoxitin 128, R 128, R 128, R 128, R 128, R 128, R 128, R
Aztreonam 0.25, S 32, R 0.25, S 64, R 0.12, S 64, R 64, R
Cefepime 128, R 128, R 8, S 128, R 32, R 32, R 32, R
Imipenem 128, R 128, R 8, R 16, R 8, R 1, S 2, I
Meropenem 128, R 128, R 2, I 32, R 1, S 2, I 2, I
Ciprofloxacin 32, R 64, R 0.06, S 128, R 0.06, S 64, R 0.06, S
Tigecycline 1, S 2, S 0.12, S 2, S 0.12, S 0.5, S 0.12, S
Colistin 0.5, S 0.5, S 0.25, S 0.5, S 0.25, S 0.5, S 0.25, S
Gentamicin 0.25, S 1, S 0.25, S 0.5, S 0.12, S 0.25, S 0.12, S
Tobramycin 8, I 16, R 0.12, S 8, I 0.12, S 0.25, S 0.12, S
Amikacin 4, S 32, I 0.25, S 8, S 0.25, S 1, S 0.25, S
Resistant genes other than blaNDM-1
blaCTX-M-15       
c
blaTEM/blaSHV / / / / / / 
d/
armA       
ISAba125       
Size of plasmid (kb) 200 200, 60e, 50e 50e 200, 70e, 40 60e, 40 200, 50e 100e
a Using the agar dilution method.
b I, intermediate; R, resistant; S, susceptible;, negative;, positive.
c blaCTX-M-15 type.
d blaTEM-1 type.
e blaNDM-1-carrying plasmid.
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a recipient, with transconjugants being selected on MacConkey
agar containing 100 g/ml of sodium azide and 8 g/ml of cefta-
zidime. Plasmids in the transconjugants were typed as described
previously (2). Plasmid sizes were determined by S1 nuclease re-
striction andpulsed-field gel electrophoresis (PFGE). The blaNDM-
1-carrying plasmids were successfully transferred from the three
index strains (E1454, F528, and E5026) to E. coli J53 at frequencies
ranging from ca. 105 to 107 (transconjugant/donor). Hybrid-
ization of the membrane blot with a probe recognizing blaNDM-1
showed that the blaNDM-1-carrying plasmids varied in size, being
ca. 200 kb in F181, ca. 60 and 50 kb in E1454, ca. 70 kb in F528, and
ca. 50 kb in E5026 (Table 2). The blaNDM-1-carrying plasmids in
this study all belonged to the IncN group. These results suggested
that the plasmids may be quite unstable, as reported previously
(14). This type of plasmid was previously known to be involved in
the transmission of VIM-1, KPC-2, and CTX-M-1 as well as
NDM-1 among K. pneumoniae isolates and has been also preva-
lent inE. coli and Salmonella species (1). Various replicon types are
involved in blaNDM-1-carrying plasmids (19), but IncN has re-
cently been found in only one NDM-1-positive E. coli strain (18).
Highly efficient transmission of blaNDM-1-carrying plasmids (21)
may explain the diversity and worldwide spread of blaNDM-1-
carrying Enterobacteriaceae.
DNA sequences of housekeeping genes were uploaded to the
multilocus sequence typing (MLST) database (http://pubmlst
.org) (5). All 4 strains belonged to sequence type (ST) 340.
GenomicDNAwas digestedwith the restriction enzymeXbaI (Ta-
kara, Tokyo, Japan) and separated using the CHEF-DR II appara-
tus (Bio-Rad, Hercules, CA). The PFGE band patterns of the four
strains were different by fewer than three bands, suggesting a
clonal relationship among the strains (Fig. 1). Although no clear
epidemiological linkage was found among the patients, the PFGE
band patterns strongly suggest clonal dissemination of a strain
within the hospital. All strains yielded ST 340, which is a single-
locus variant of ST 258, the dominant ST of KPC3-producing K.
pneumoniae worldwide (9) and the ST of one of two KPC2-pro-
ducing K. pneumoniae found in South Korea (22), and this type,
like the NDMKP of this study, has been shown to be gentamicin
susceptible but tobramycin and amikacin resistant (12). ST 340
has already been found in NDMKP isolates from Oman, the
United Kingdom, and Canada, of which two seem to be linked to
India (16, 19). The clone of the NDMKP isolate of this study may
possibly have been imported from regions of NDM endemicity,
even though no direct epidemiologic links were found.
In this study, the first emergence of NDMKP ST 340 strains in
South Korea suggested that NDMKP strains might have been in-
troduced earlier in the hospital and were already spread nosoco-
mially. The one isolate revealing susceptibleMICs to carbapenems
implied the difficulty of detecting NDMKP, and resistance mech-
anism-based screening for CRE is required to prevent the spread
of NDMKP.
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